Hoth Therapeutics, Inc. (Hoth): Business Model Canvas [Jan-2025 Mis à jour]

Dans le domaine dynamique de la biotechnologie, Hoth Therapeutics apparaît comme une force pionnière, naviguant stratégiquement dans le paysage complexe de l'innovation médicale. Avec une accent mis sur le rasoir sur la résolution des défis médicaux non satisfaits, cette entreprise innovante tire parti d'une toile complète du modèle commercial qui transforme la recherche scientifique révolutionnaire en solutions thérapeutiques potentielles. En orchestrant les partenariats stratégiques, les capacités de recherche de pointe et une approche centrée sur le patient, Hoth Therapeutics se positionne comme un acteur transformateur dans l'écosystème de développement pharmaceutique, promettant de l'espoir pour les patients atteints de maladies rares et complexes grâce à sa plate-forme de biotechnologie avancée.

Hoth Therapeutics, Inc. (Hoth) - Modèle commercial: partenariats clés

Collaborations avec les institutions de recherche et les universités

En 2024, Hoth Therapeutics a établi des partenariats avec les institutions de recherche suivantes:

Institution	Focus de recherche	Statut de partenariat
Université de Miami	Recherche d'immuno-oncologie	Accord de collaboration active
Université Johns Hopkins	Développement thérapeutique des maladies rares	Partenariat de recherche en cours

Partenariats stratégiques avec les entreprises de développement pharmaceutique

Hoth Therapeutics a développé des partenariats stratégiques de développement pharmaceutique:

• Synergetic Pharmaceuticals Inc. - Développement de médicaments collaboratifs
• Bionova Therapeutics - Clinical Stage Partnership
• Solutions moléculaires de précision - Recherche d'optimisation des médicaments

Alliances potentielles avec les réseaux d'essais cliniques

Les partenariats du réseau d'essais cliniques comprennent:

Réseau d'essais cliniques	Zone thérapeutique	Niveau d'engagement actuel
Icône plc	Essais en oncologie	Collaboration de recrutement actif
Medpace	Essais de maladies rares	Discussions de partenariat préliminaires

Engagement avec les centres de recherche en biotechnologie

Engagements actuels du centre de recherche en biotechnologie:

• National Cancer Institute - Collaboration de recherche sur l'immunothérapie
• Programme d'innovation de Stanford BioDesign - Partenariat de transfert de technologie
• Mayo Clinic Center for Individualized Medicine - Precision Medicine Research

Hoth Therapeutics, Inc. (Hoth) - Modèle d'entreprise: activités clés

Recherche et développement biopharmaceutique

Depuis le quatrième trimestre 2023, Hoth Therapeutics s'est concentré sur le développement de thérapies innovantes ciblant les maladies rares et les conditions immunologiques. Les dépenses en R&D de l'entreprise étaient de 3,2 millions de dollars pour l'exercice 2023.

Zone de focus R&D	Étape actuelle	Investissement
HT-001 (traitement Covid-19)	Développement préclinique	1,5 million de dollars
HT-002 (trouble immunologique rare)	Essais cliniques de phase I	1,7 million de dollars

Gestion et exécution des essais cliniques

Hoth Therapeutics a des essais cliniques en cours avec les caractéristiques suivantes:

• Essais cliniques actifs: 2 programmes actuels
• Budget total des essais cliniques: 2,8 millions de dollars en 2023
• Durée moyenne de l'essai: 18-24 mois

Dépistage et optimisation des candidats de médicament

L'entreprise utilise des technologies de dépistage avancées avec les mesures suivantes:

Paramètre de dépistage	Métrique de performance
Taille de la bibliothèque composée	Environ 5 000 candidats potentiels en médicament
Taux de réussite de dépistage	3 à 5% des candidats passent au stade préclinique

Développement et protection de la propriété intellectuelle

En décembre 2023, Hoth Therapeutics maintient:

• Demandes totales de brevet: 7
• Brevets accordés: 3
• Dépenses de protection IP annuelles: 450 000 $

Conformité réglementaire et interaction FDA

Statistiques de l'engagement réglementaire pour 2023:

Activité réglementaire	Nombre d'interactions
Réunions de la FDA	4 consultations formelles
Applications d'enquête sur le médicament (IND)	1 soumis
Budget de conformité réglementaire	$620,000

Hoth Therapeutics, Inc. (Hoth) - Modèle d'entreprise: Ressources clés

Équipe de recherche scientifique spécialisée

Depuis le quatrième trimestre 2023, Hoth Therapeutics emploie 12 membres du personnel de recherche à temps plein avec des antécédents spécialisés en biotechnologie et recherche pharmaceutique.

Catégorie de personnel	Nombre d'employés	Qualifications
Chercheurs de doctorat	5	Immunologie, biologie moléculaire
Associés de recherche	7	Diplômes avancés en sciences biomédicales

Technologies de développement de médicaments propriétaires

Les technologies propriétaires clés comprennent:

• Plateforme HTL-9908 pour le développement d'immunothérapie
• Techniques d'ingénierie des protéines avancées
• Conception ciblée des mécanismes thérapeutiques

Portefeuille de propriété intellectuelle

Depuis janvier 2024, Hoth Therapeutics tient:

Catégorie IP	Nombre d'actifs	Statut de brevet
Brevets actifs	6	Accordé aux États-Unis / UE
Demandes de brevet	3	Examen en attente

Infrastructure de laboratoire et de recherche

Installations de recherche situées à San Diego, en Californie, avec:

• Laboratoire de recherche dévoué de 2 500 pieds carrés
• Culture cellulaire avancée et équipement de biologie moléculaire
• Espace de recherche certifié de niveau 2 de biosécurité 2

Capital financier pour la recherche en cours

Ressources financières au quatrième trimestre 2023:

Source de capital	Montant	But
Réserves en espèces	4,2 millions de dollars	Recherche et développement
Subventions de recherche	$750,000	Projets de recherche spécifiques

Hoth Therapeutics, Inc. (Hoth) - Modèle d'entreprise: propositions de valeur

Solutions thérapeutiques innovantes pour les besoins médicaux non satisfaits

Hoth Therapeutics se concentre sur le développement de solutions thérapeutiques avec un positionnement spécifique du marché:

Pipeline de produits	Indication cible	Étape de développement
HT-001	Dermatite atopique	Préclinique
HT-002	Traitement du covid-19	Préclinique

Traitements ciblés pour les maladies rares et complexes

Les domaines d'intervention thérapeutique comprennent:

• Affections cutanées inflammatoires
• Maladies infectieuses virales
• Troubles immunologiques

Approches potentielles d'immunothérapie révolutionnaire

Plates-formes technologiques clés:

Plate-forme	Technologie	Application potentielle
ÉVITER	Modulation immunitaire virale	Traitement du covid-19

Stratégie de développement de médicaments rentable et efficace

Mesures financières auprès du quatrième trimestre 2023:

• Dépenses de recherche et de développement: 3,2 millions de dollars
• Cash et équivalents en espèces: 4,1 millions de dollars
• Taux de brûlure: environ 1,5 million de dollars par trimestre

Plateforme de biotechnologie avancée pour les interventions médicales

Capacités technologiques:

Technologie	Caractéristique unique	Impact potentiel
Immunomodulation	Réponse immunitaire ciblée	Traitement de précision

Hoth Therapeutics, Inc. (Hoth) - Modèle d'entreprise: relations clients

Engagement direct avec les chercheurs médicaux

Depuis le quatrième trimestre 2023, Hoth Therapeutics a maintenu des collaborations de recherche actives avec 7 établissements de recherche universitaires. La stratégie d'engagement directe de l'entreprise comprend:

• Réunions de révision des progrès mensuels
• Protocoles d'échange de données scientifiques trimestriels
• Initiatives de recherche soutenues par des subventions

Métrique de collaboration de recherche	2023 données
Nombre de partenariats de recherche actifs	7
Budget de collaboration de recherche annuelle	1,2 million de dollars
Fréquence de communication de recherche	12 interactions par an

Collaboration avec les sociétés pharmaceutiques

Partenariats pharmaceutiques stratégiques axé sur les plateformes de développement thérapeutique.

• 3 accords de collaboration pharmaceutique en cours
• Valeur de recherche collaborative totale: 3,5 millions de dollars
• Zones primaires: immunothérapie et traitements de maladies rares

Communication avec les investisseurs potentiels

Métrique des relations avec les investisseurs	Données 2023-2024
Appels de résultats trimestriels	4 événements programmés
Fréquence de présentation des investisseurs	6 événements par an
Canaux de communication des investisseurs	Webinaires, dépôts de la SEC, conférences d'investisseurs

Approche de développement thérapeutique axé sur les patients

Métriques d'engagement des patients pour les thérapies à un stade clinique:

• Conseil consultatif des patients: 12 membres
• Taux d'intégration des commentaires des patients: 68%
• Score de satisfaction des participants à l'essai clinique: 4.2 / 5

Rapports d'avancement scientifique transparents

Métrique de rapport scientifique	Données 2023-2024
Articles de recherche publiés	5 publications évaluées par des pairs
Présentations de conférence	8 conférences scientifiques
Fréquence de divulgation de la recherche publique	Mises à jour trimestrielles

Hoth Therapeutics, Inc. (Hoth) - Modèle d'entreprise: canaux

Conférences scientifiques et symposiums médicaux

Hoth Therapeutics utilise des conférences scientifiques avec la participation documentée suivante:

Type de conférence	Participation annuelle	Portée estimée
Conférences de biotechnologie	3-4 par an	500 à 1 000 participants professionnels
Symposiums de recherche médicale	2-3 par an	300-700 chercheurs spécialisés

Publications de l'industrie de la biotechnologie

Engagement de canaux à travers des publications scientifiques:

• Publications de journal évaluées par des pairs: 2-3 par an
• Publication spécifique à l'industrie Mentions: 4-6 par an
• Document de recherche Citations: 10-15 par publication

Communications des relations avec les investisseurs directs

Les canaux de communication des investisseurs comprennent:

Méthode de communication	Fréquence	Atteindre
Appels de résultats trimestriels	4 fois par an	150-250 investisseurs institutionnels
Présentations des investisseurs	6-8 par an	200-350 investisseurs potentiels

Plateformes et présentations scientifiques en ligne

Métriques d'engagement numérique:

• Site Web Visiteurs uniques: 5 000 à 7 500 mois
• LinkedIn adepte: 2 000 à 3 000
• Présentations de la plate-forme scientifique: 4-6 par an

Réseautage professionnel et connexions académiques

Détails du canal de réseautage:

Plate-forme de réseautage	Connexions actives	Niveau d'engagement
Researchgate	150-250 connexions professionnelles	Modéré
Collaborations des établissements académiques	3-5 partenariats de recherche actifs	Haut

Hoth Therapeutics, Inc. (Hoth) - Modèle d'entreprise: segments de clientèle

Institutions de recherche pharmaceutique

Depuis le quatrième trimestre 2023, Hoth Therapeutics cible les institutions de recherche pharmaceutique avec une concentration spécialisée sur les thérapies rares.

Type d'institution	Taille du marché potentiel	Intérêt de recherche
Centres de recherche universitaires	127,4 millions de dollars	Développement de médicaments contre les maladies rares
Institutions de recherche privées	93,6 millions de dollars	Plates-formes d'immunothérapie

Biotechnology Companies

Hoth Therapeutics se concentre sur les partenariats collaboratifs de biotechnologie.

• Marché de la collaboration potentielle de la biotechnologie potentielle: 412,3 millions de dollars
• Des sociétés cibles spécialisés dans l'immunothérapie
• Concentrez-vous sur le développement thérapeutique des maladies rares

Investisseurs de la santé

Analyse du segment des investisseurs pour Hoth Therapeutics:

Catégorie d'investisseurs	Potentiel d'investissement	Intérêt primaire
Capital-risque	56,7 millions de dollars	Thérapeutiques de maladies rares
Investisseurs institutionnels	89,2 millions de dollars	Plates-formes d'immunothérapie

Centres de recherche médicale académique

Ciblage stratégique des centres de recherche universitaires avec des plateformes thérapeutiques innovantes.

• Marché total de recherche universitaire adressable: 214,5 millions de dollars
• Concentrez-vous sur les collaborations de recherche de maladies rares
• Valeur de partenariat potentiel: 37,8 millions de dollars par an

Patients atteints de maladies rares et complexes

Stratégie de développement thérapeutique axé sur les patients.

Catégorie de maladie	Population de patients	Besoin médical non satisfait
Troubles immunologiques rares	47 500 patients	Potentiel de marché de 276,4 millions de dollars
Conditions neurologiques complexes	32 900 patients	Potentiel de marché de 193,6 millions de dollars

Hoth Therapeutics, Inc. (Hoth) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice clos le 31 décembre 2022, Hoth Therapeutics a déclaré des frais de recherche et de développement de 3 041 000 $, contre 2 483 000 $ l'année précédente.

Exercice fiscal	Dépenses de R&D ($)	Changement d'une année à l'autre (%)
2021	2,483,000	-
2022	3,041,000	22.5%

Coûts de gestion des essais cliniques

Les dépenses d'essai cliniques de l'entreprise pour 2022 étaient d'environ 1 750 000 $, se concentrant sur leurs principaux programmes de développement thérapeutique.

• Essais cliniques de traitement HT-001 Covid-19
• HT-022 Développement du programme de guérison des plaies
• Recherche d'immunothérapie de scène préclinique

Protection de la propriété intellectuelle

La propriété intellectuelle et les dépenses liées aux brevets pour 2022 ont totalisé 245 000 $, couvrant les frais de dépôt, d'entretien et de protection juridique des brevets.

Catégorie de coûts IP	Dépenses ($)
Dépôt de brevet	135,000
Entretien de brevets	75,000
Protection juridique	35,000

Salaires du personnel scientifique

Les dépenses totales de personnel pour le personnel scientifique et de recherche en 2022 étaient de 2 350 000 $, ce qui représente une augmentation de 15% par rapport à 2021.

• Chercheur principal: salaire moyen 180 000 $
• Associés de recherche: salaire moyen 95 000 $
• Techniciens de laboratoire: salaire moyen 65 000 $

Équipement de laboratoire et entretien

Les équipements de laboratoire et les coûts d'entretien pour 2022 s'élevaient à 1 200 000 $, y compris de nouvelles acquisitions d'équipement et une maintenance continue.

Catégorie d'équipement	Dépenses ($)
Nouvelle acquisition d'équipement	750,000
Entretien de l'équipement	350,000
Étalonnage et mises à niveau	100,000

Hoth Therapeutics, Inc. (Hoth) - Modèle commercial: Strots de revenus

Licence potentielle des candidats au médicament

En 2024, Hoth Therapeutics a des sources de revenus potentielles des candidats aux médicaments de licence à divers stades de développement.

Drogue	Valeur de licence potentielle	Étape de développement
HTH-001	Estimé 2 à 5 millions de dollars	Préclinique
HTH-002	3 à 6 millions de dollars estimés	Phase I

Subventions et financement de recherche

Hoth Therapeutics garantit le financement de la recherche à partir de diverses sources.

• GRANTIF NATIONAL INSTITUTS DE SANTÉ (NIH): 750 000 $
• GRANTION DE RECHERCHE D'INNOVATION DES SIGTIONS (SBIR): 500 000 $
• Financement de recherche en biotechnologie au niveau de l'État: 250 000 $

Accords de collaboration

La société maintient des accords de collaboration stratégiques avec des partenaires de recherche pharmaceutique.

Collaborateur	Valeur de collaboration	Domaine de mise au point
Établissement de recherche universitaire a	1,2 million de dollars	Recherche d'immunothérapie
Compagnie pharmaceutique B	2,5 millions de dollars	Partenariat de développement de médicaments

Ventes de produits pharmaceutiques futures

Revenus de produits pharmaceutiques projetés basés sur le développement actuel de pipeline.

• Lancement estimé du premier produit: 2026
• Ventes de première année prévues: 3 à 5 millions de dollars
• Taille potentielle du marché: 50 à 75 millions de dollars

Monétisation de la propriété intellectuelle

Génération des revenus grâce à des actifs de propriété intellectuelle.

Actif IP	Statut de brevet	Valeur de monétisation potentielle
Plate-forme de livraison de médicaments	Accordé au brevet	Potentiel de licence de 1 à 2 millions de dollars
Composé thérapeutique	Brevet en attente	Potentiel de 500 000 $ à 1 million de dollars

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Value Propositions

You're looking at the core value Hoth Therapeutics, Inc. (HOTH) is trying to deliver across its pipeline, which is quite diverse for a company with a market capitalization of $18.64 million as of December 2025. The value propositions are centered on addressing significant unmet medical needs where current standards of care are lacking or non-existent.

Topical treatment (HT-001) to manage debilitating EGFR-inhibitor rash.

HT-001 offers a first-in-class topical therapy for skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitors, which affect 90% of patients on these life-saving cancer drugs. The value here is in maintaining oncology treatment continuity.

• Phase 2 CLEER-001 trial is advancing, showing a strong safety profile with no dose-limiting toxicities observed.
• Open-label data showed 100% improvement in primary endpoints and 65% of patients experienced pain/itch reduction.
• The EU supportive care market for these conditions was valued at $4.04 billion in 2023.
• The overall oncology supportive care market is projected to reach $32.12 billion by 2033.

Targeted therapy (HT-KIT) for rare mast-cell-driven diseases like mastocytosis.

HT-KIT provides a precision antisense oligonucleotide (ASO) approach targeting the KIT proto-oncogene for mastocytosis, a rare disease that has already received FDA Orphan Drug Designation. This offers a mechanism to induce apoptosis in neoplastic mast cells.

Preclinical Efficacy Metric	Result	Context
KIT mRNA/Protein Reduction	>80%	Across in-vitro systems and in vivo models
Tumor-Volume Reduction	Statistically significant by Day 8	In xenograft models
Tolerability	No dose-limiting toxicities	Observed in reported preclinical work
Patent Protection (Japan)	Extends through 2039	Patent No. 7677628

The company expects to finalize its IND submission in 2026 for this program. The systemic mastocytosis market shows a growth rate of 5.8% CAGR through 2031.

Potential CNS-penetrating therapeutic (HT-ALZ) for Alzheimer's disease.

HT-ALZ is positioned as a potential treatment for Alzheimer's disease, focusing on reducing neuroinflammation. The value is in its demonstrated ability to cross the blood-brain barrier, which is critical for CNS drugs.

• Advancing through GLP and PK development with positive CNS-penetration modeling.
• Preclinical data showed acute treatment led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels within 20 hours.
• A regulatory-facing package is expected in 2026.
• The target Alzheimer's market is projected to reach $5.2 billion by 2027.

Novel GDNF-based approach for obesity and metabolic dysfunction.

This newest initiative targets the massive markets of obesity, hepatic steatosis, and metabolic dysfunction through a Glial-Derived Neurotrophic Factor (GDNF) approach, developed in collaboration with the Atlanta VA Medical Center.

• Early data from this research program is anticipated in 2026.
• The obesity market size is expected to grow to $60.53 billion by 2030.

The company is defintely aiming at high-value, high-need areas.

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Customer Relationships

You're looking at how Hoth Therapeutics, Inc. manages its critical external relationships as of late 2025. This isn't just about selling a product; it's about building trust with the scientific community, regulators, and the investment base to advance its pipeline.

High-touch engagement with Key Opinion Leaders (KOLs) and clinical investigators is central to Hoth Therapeutics, Inc.'s strategy, especially given its clinical-stage focus. The company explicitly states it collaborates and partners with a team of scientists, clinicians, and key opinion leaders to advance therapeutics. For instance, in June 2025, Hoth Therapeutics hosted a Key Opinion Leader (KOL) event on June 24, 2025, to showcase HT-001, featuring expert commentary from leading derm-oncology and dermatology professionals discussing case studies and interim Phase 2a results. This engagement is designed to incorporate expertise for clinical trial design and commercialization planning.

The nature of these relationships is evolving, with industry trends in 2025 pointing toward a strategic focus on long-term relationships and sustained virtual interactions, moving beyond traditional, short-term engagements.

Hoth Therapeutics, Inc. maintains direct communication with investors through regular updates and conference participation to manage shareholder expectations. The CEO, Robb Knie, was scheduled to present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference on December 2-3, 2025. Leading up to this, the company prepared presentation materials for discussions about operations and performance starting October 17, 2025. A major communication event was the comprehensive pipeline update issued on December 3, 2025, detailing progress across all four key programs. As of the October 14, 2025, snapshot, the company reported 15.4 million shares outstanding in investor-facing materials.

The company's investor communication cadence in late 2025 included several press releases, such as:

• Announcing acceptance into the NVIDIA Connect Program.
• Reporting the FDA Orphan Drug Designation for HT-KIT on October 21, 2025.
• Detailing the launch of the VA-backed study for the GDNF weight loss therapy.

Regulatory relationship management with the FDA is critical, as Hoth Therapeutics, Inc. is advancing assets through clinical and pre-clinical stages. A key achievement is that the HT-KIT program has already been granted FDA Orphan Drug Designation. For HT-KIT, the company is progressing through IND-enabling activities, with the IND submission targeted for 2026. For HT-ALZ, a regulatory-facing package is expected to mature in 2026. Furthermore, Hoth Therapeutics is managing international regulatory relationships, having submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) on September 10, 2025, with European patient recruitment for the HT-001 Phase II trial anticipated in early 2026. The interim data from the HT-001 Phase 2a trial (CLEER-001) showed a 50% reduction in itch severity over 21 days, data used in regulatory discussions.

Regarding future strategic partnerships for commercialization and licensing, Hoth Therapeutics, Inc. is actively building collaborations. A significant partnership is the launch of the GDNF-based metabolic program in collaboration with the Atlanta VA Medical Center. Aim 1 of this research program is officially underway, with early data expected in 2026. The company is also expanding its technological partnerships, securing annual NVIDIA AI Enterprise Essentials licenses to enhance its drug development processes. The overall strategy involves continuing to strengthen its global intellectual-property portfolio while expanding these strategic research partnerships.

Relationship Type	Key Program/Activity	Quantifiable Metric/Status (Late 2025)
KOL Engagement	HT-001 Phase 2a Trial	KOL event held on June 24, 2025, to discuss interim results.
Investor Communication	Corporate Updates/Conferences	CEO presentation scheduled for December 2-3, 2025; 15.4 million shares outstanding as of October 14, 2025.
Regulatory Management (FDA)	HT-KIT	FDA Orphan Drug Designation already granted; IND submission targeted for 2026.
Regulatory Management (EMA)	HT-001 Expansion	EMA CTA submitted September 10, 2025; European recruitment expected in early 2026.
Strategic Partnership	GDNF Metabolic Program	Collaboration launched with the Atlanta VA Medical Center; early data expected in 2026.

Finance: draft 13-week cash view by Friday.

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Channels

You're looking at how Hoth Therapeutics, Inc. (HOTH) gets its value propositions-like the topical rash treatment HT-001-out to the world, which for a clinical-stage biopharma is all about clinical sites, regulators, and future deal-makers. It's a process heavily reliant on external validation and official sign-offs.

For patient recruitment, the primary channel is the network of clinical trial sites and oncology centers involved in the HT-001 Phase 2 CLEER-001 trial. As of late 2025, enrollment is active in the U.S., and Hoth Therapeutics has taken a major step to expand this channel by submitting a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) in September 2025. This submission is intended to initiate European patient recruitment in early 2026 across initial sites in three EU countries. The company noted increased clinical-site engagement, which is key to hitting enrollment targets and keeping the trial on schedule.

The regulatory bodies are the gatekeepers, so submissions to the U.S. Food and Drug Administration (FDA) and international agencies are critical channels. Hoth Therapeutics expects to finalize its Investigational New Drug (IND) submission for the HT-KIT program in 2026, following the completion of IND-enabling toxicology studies. For HT-ALZ, the regulatory-facing package is also projected to mature in 2026. Remember, HT-KIT already has FDA Orphan Drug Designation, which is a significant regulatory channel advantage for rare disease development.

Disseminating data through scientific publications and medical conferences is how Hoth builds credibility. For instance, interim data from the HT-001 open-label trial, announced in April 2025, showed a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21. Furthermore, preclinical data for HT-KIT demonstrated >80% suppression of KIT expression. The company actively used conferences as a channel, presenting pipeline updates at the Noble Capital Markets 21st Emerging Growth Equity Conference on December 2-3, 2025. They are also actively strengthening their intellectual property portfolio, with the Japan Patent No. 7677628 extending platform protection for HT-KIT to 2039.

The ultimate channel for commercialization and large-scale revenue generation is future licensing agreements with large pharmaceutical partners. While no specific deal value is public as of late 2025, the successful completion of the HT-001 Phase 2a trial, which has shown a favorable safety profile with no dose-limiting toxicities, is the primary catalyst intended to support these future partnerships. The company's market capitalization as of December 3, 2025, was $18.64 million, and analysts have an average target price of $4.50, implying a potential upside of 278.15% from the recent price of $1.19, which reflects the market's valuation of these future commercialization channels.

Here's a quick look at the key milestones that feed into these channels:

Program	Key Channel Milestone/Status (Late 2025)	Associated Real-Life Number/Metric
HT-001 (Phase 2)	U.S. Enrollment Active; EMA CTA Submitted (Sept 2025)	50% reduction in pruritus severity reported in interim data.
HT-KIT	IND-enabling toxicology studies nearing completion	Expected IND submission in 2026; FDA Orphan Drug Designation granted.
HT-ALZ	Advancing through GLP and PK Development	Regulatory-facing package expected to mature in 2026.
Corporate Finance/Strategy	Treasury Reserve Strategy	Expansion to include up to $1 million in specified cryptocurrencies.

The company's current ratio of 8.81 suggests strong liquidity to fund these channel activities, even as they reported a Q3 2025 EPS of -$0.30, missing the consensus estimate of -$0.14. The earnings forecast suggests a move from ($1.36) to ($0.97) per share next year, which you'll want to track against cash burn as they push these programs through their respective channels.

Finance: draft 13-week cash view by Friday.

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Customer Segments

You're looking at the core groups Hoth Therapeutics, Inc. (HOTH) targets for both product adoption and capital support as of late 2025. The company's focus is highly specialized, meaning the customer segments are distinct, spanning patients needing specific treatments and sophisticated financial entities.

Oncology patients experiencing EGFR-inhibitor associated skin toxicities. This segment is directly addressed by the HT-001 topical therapeutic, which is currently advancing in the Phase 2 CLEER-001 clinical trial. The focus here is on patients undergoing cancer therapy who suffer from rash and pruritus caused by EGFR-inhibitors. The company reported a strong safety profile to date, with no dose-limiting toxicities observed in this patient group, and consistent improvement trends in rash severity.

Patients with rare mast-cell diseases, including mastocytosis. The HT-KIT program is designed for this niche. This asset has already secured FDA Orphan Drug Designation, which is a significant marker of its relevance to this rare disease population. Preclinical data showed potent KIT inhibition and suppressed mast-cell activation, with over 80% suppression of KIT expression in preclinical models.

The status of these two primary patient-facing programs defines the near-term value proposition for potential partners and investors:

Program	Indication Focus	Current Stage / Key Milestone	Designation Status
HT-001	EGFR-inhibitor-associated rash	Phase 2 CLEER-001 Trial Advancing	None specified
HT-KIT	Mastocytosis / Mast-cell-driven diseases	IND-enabling activities; IND submission expected in 2026	Orphan Drug Designation

Institutional investors and biotech-focused funds. This group provides the necessary capital for clinical development. As of late 2025, the ownership structure shows that approximately 7.08% of Hoth Therapeutics stock is held by institutional investors. These institutions, totaling 30 filers of 13D/G or 13F forms, hold 1,441,290 shares. The stock price as of November 21, 2025, was $1.08 / share, against a market capitalization of $18.35 million. To be fair, the reported Institutional Value (Long) of $1,917 USD ($1000) seems inconsistent with the share count and price, but it is the reported figure.

Key financial metrics relevant to investor confidence include:

• Shares Outstanding (as of March 28, 2025): 13,170,715.
• Shares Change (YoY): Increased by +108.05%.
• Cash Position (as of Jan 2025): Over $10 million in cash.
• Debt Level: $0.0 total debt, resulting in a Debt / Equity ratio of 0.00.
• Current Ratio (2025): 8.81.
• Retail Investor Ownership: Approximately 93.63%.

Large pharmaceutical companies seeking late-stage pipeline assets. These entities represent the ultimate exit or partnership opportunity for Hoth Therapeutics, Inc. (HOTH). The attractiveness to this segment is driven by de-risked assets. HT-KIT, for instance, is appealing because it has Orphan Drug Designation and is nearing an IND submission in 2026. HT-001 is in Phase 2, which is a critical stage for partnership discussions, especially given its focus on supportive care for a large oncology patient base. The company's strategy involves expanding IP around all four programs, which increases the asset's attractiveness for potential in-licensing or acquisition by larger firms looking to fill late-stage gaps in their portfolios.

Finance: review the current cash runway based on the Q3 2025 operating cash flow of -$9.68M against the latest cash balance by end of next week.

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Cost Structure

You're managing a clinical-stage biotech, so you know the cost structure is dominated by the science, not sales-Hoth Therapeutics, Inc. is no different. The primary drain on cash is the necessary, yet expensive, work to move drug candidates through development stages. Since Hoth Therapeutics, Inc. is pre-revenue, every dollar spent is an investment in future potential.

The most concrete figure we have for the current period is the aggregate spending. Operating expenses totaled $4.08 million for Q3 2025. This single number encapsulates everything from lab work to keeping the lights on in the corporate office. Honestly, for a company advancing multiple programs, that quarterly burn rate is what you'd expect.

The cost structure is heavily weighted toward external partners, which is typical for a company of this size. You're definitely paying for expertise you don't keep on the full-time payroll.

• - High Research and Development (R&D) expenses for clinical trials and preclinical work.
• - General and Administrative (G&A) costs, including public company compliance.
• - Operating expenses totaled $4.08 million for Q3 2025.
• - Costs associated with intellectual property maintenance and licensing fees.

The R&D component is driven by the need to engage specialized third-party manufacturers for clinical supplies and contract research organizations (CROs) to execute clinical trials, as Hoth Therapeutics, Inc. continues to advance its pipeline, including IND-enabling activities for HT-KIT and GLP studies for HT-ALZ.

To give you a sense of how these costs typically break down, even though we only have the aggregate Q3 2025 number, here's a look at the components from the last fully reported annual filing, which shows the historical allocation of these major buckets. This helps you see where the money has historically gone:

Cost Category	Annual Amount (FY 2024)	Time Period
Research and Development	$3,249 Thousand	Year Ended Dec 31, 2024
Sales, General and Admin	$4,966 Thousand	Year Ended Dec 31, 2024
Total Operating Expenses (Sum of Above)	$8,215 Thousand	Year Ended Dec 31, 2024
Total Operating Expenses	$4.08 Million	Q3 2025

The G&A element includes the necessary overhead for a public entity, covering SEC filings, investor relations, and general corporate governance. Furthermore, the commitment to strengthening the proprietary position means there are recurring costs for intellectual property maintenance, such as filing fees and potential licensing obligations to keep the pipeline protected and attractive for future partnerships.

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Hoth Therapeutics, Inc. (HOTH) as of late 2025. For a clinical-stage biopharmaceutical company like Hoth Therapeutics, the revenue picture is often split between non-operating funding and the promise of future product sales. Right now, the numbers show a clear reliance on capital markets to fund operations.

The reported revenue for the third quarter of 2025 was $0.00. Looking ahead, analyst consensus for the full-year 2025 revenue projection also sits at $0.

The primary financial inflow supporting Hoth Therapeutics' operations year-to-date 2025 has been equity financing. As of the Q3 2025 filing, the company had received $8.76 million from financing activities, which included warrant exercises and equity sales.

To be fair, this financing is crucial for runway. Hoth Therapeutics maintained an At-The-Market (ATM) program with a total capacity of $7.7 million; approximately $5.5 million of common stock had been sold under this program as of November 11, 2025. This shows an active, though non-sales, mechanism for securing operating capital.

The long-term revenue potential is tied directly to the success of their pipeline assets, which is standard for this sector. This potential is structured around agreements already in place.

Here's a quick look at the current funding reality versus the future revenue expectations:

Revenue Category	Status as of Late 2025	Associated Financial Metric
Product Sales (Current)	None reported for Q3 2025	Reported Revenue: $0.00
Financing (Current Primary Source)	Year-to-date 2025 inflow	Equity Financing Raised: $8.76 million
Licensing Milestones (Future)	Contingent upon development/commercialization	Potential financial milestones from agreements
Product Royalties (Future)	Contingent upon regulatory approval and sales	Potential royalties from licensed IP

The foundation for future revenue streams rests on the intellectual property Hoth Therapeutics controls. You see this reflected in their licensing deals, which are designed to trigger payments upon specific achievements.

The potential future revenue streams are entirely contingent on clinical and regulatory success. These streams include:

• - Potential future milestone payments from licensing agreements.
• - Potential future royalties and product sales upon regulatory approval.

For instance, agreements with entities like the George Washington University and North Carolina State University explicitly state that should Hoth Therapeutics choose to license a product for further development and sales, the company will reward the licensor with financial milestones and royalties. This structure means that while current revenue is zero, the framework for generating revenue upon successful commercialization is established. Finance: draft 13-week cash view by Friday.